On the stock market since 1992, it operates in the world of health and science. It has 6,374 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 12% a year over the last 4 years. Every year shown ended in profit.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 40% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 12% a year on average.
Over the last 12 months, company executives reported 18 buys and 13 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $96.00 — 23% above today’s price.
The company’s market value is 83 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 21/100.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, USPH sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: USPH is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.